Denovo Biomarkers, ALS-ETF to explore personalized medicine in amyotrophic lateral sclerosis

Biotech company, nonprofit group form partnership

SAN DIEGO — A biotech company and a nonprofit organization are looking into new ways to treat patients with the devastating degenerative disorder commonly known as Lou Gehrig's disease.

The ALS Emergency Treatment Fund and Denovo Biomarkers announced Friday a deal to explore the use of personalized medicine in treating patients with the disease, known medically as amyotrophic lateral sclerosis. The two said the approach could accelerate drug development in ALS and other life-threatening disorders.

"This exciting relationship with Denovo Biomarkers may accelerate the development of drugs for ALS and may help us provide useful information for patients and physicians," ALS-ETF managing director Jess Rabourn said.


Login or Register to post a comment.